Group 1 - The core viewpoint of the article highlights the financial performance of Renhe Pharmaceutical for the third quarter of 2023, indicating a decline in revenue and net profit compared to the previous year [1] Group 2 - For the first three quarters of 2023, Renhe Pharmaceutical reported revenue of approximately 2.833 billion yuan, a year-on-year decrease of 10.07% [1] - The net profit attributable to shareholders of the listed company was about 379 million yuan, reflecting a year-on-year decrease of 8.79% [1] - The basic earnings per share stood at 0.2708 yuan, also down by 8.79% year-on-year [1] - As of the report date, the market capitalization of Renhe Pharmaceutical was 8.6 billion yuan [2]

Group 1 - The core viewpoint of the article highlights that Renhe Pharmaceutical reported a revenue of 858 million yuan in the third quarter, representing a year-on-year increase of 9.16% [1] - The net profit for the third quarter was 88.71 million yuan, showing a year-on-year growth of 13.00% [1] Group 2 - For the first three quarters, the company's revenue totaled 2.833 billion yuan, which is a year-on-year decline of 10.07% [1] - The net profit for the first three quarters was 379 million yuan, reflecting a year-on-year decrease of 8.79% [1]

Financial Performance - The company's operating revenue for Q3 2025 reached ¥858,360,283.90, representing a year-on-year increase of 9.16%[5] - Net profit attributable to shareholders for the same period was ¥88,708,927.17, up 13.00% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥70,147,440.28, an increase of 37.16% year-on-year[5] - Total revenue for the period was ¥2,833,451,760.31, a decrease of approximately 10.06% from ¥3,150,637,679.36 in the previous period[18] - Operating profit for the period was ¥616,982,001.53, reflecting a decline of about 10.05% compared to ¥685,900,363.74 in the previous period[18] - The net profit for the current period is $469.11 million, a decrease of 8.9% compared to $514.90 million in the previous period[19] - The total comprehensive income attributable to the parent company is $379.14 million, down from $415.68 million in the previous period[19] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥8,103,800,378.35, reflecting an increase of 8.30% from the end of the previous year[5] - Total assets increased to ¥8,103,800,378.35, up from ¥7,482,460,028.05 at the beginning of the period, representing a growth of 8.27%[17] - Total liabilities rose to ¥1,060,262,812.30, an increase of 56.67% from ¥676,477,512.41 at the start of the period[17] - Current assets totaled ¥5,222,277,962.93, up from ¥4,819,813,607.66, indicating a growth of 8.38%[17] - Cash and cash equivalents decreased to ¥1,095,165,834.75 from ¥2,328,656,330.79, a decline of 53.06%[17] - Inventory decreased to ¥399,721,379.54 from ¥486,938,133.84, a reduction of 17.91%[17] - Long-term equity investments slightly decreased to ¥31,463,449.98 from ¥32,402,242.05, a decline of 2.91%[17] Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥840,484,263.13, a significant increase of 181.70%[5] - The net cash flow from operating activities is $840.48 million, significantly up from $298.36 million in the previous period, indicating improved operational efficiency[21] - The total cash and cash equivalents at the end of the period is $1.07 billion, compared to $465.75 million at the end of the previous period, reflecting a strong liquidity position[22] - Cash inflow from investment activities is $6.56 billion, an increase from $4.97 billion in the previous period, showing robust investment returns[21] - The cash received from investment income rose by 65.50% to CNY 59,326,090.03, attributed to increased cash inflows from long-term large-denomination certificates and financial management products[11] - The cash outflow for the acquisition of fixed assets decreased by 76.38% to CNY 56,124,503.12, indicating reduced capital expenditures compared to the previous year[11] - The company experienced a 26.79% decrease in selling expenses, totaling ¥263,387,663.72, mainly due to reduced salary and advertising costs[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 97,731, with the largest shareholder holding 23.24% of the shares[13] - The largest shareholder, Renhe (Group) Development Co., Ltd., holds 325,299,386 shares, representing 23.24% of the total shares[13] Tax and Regulatory Information - The company reported a 51.19% decrease in tax payments, totaling CNY 236,942,118.38, due to a decline in revenue and policy impacts[11] - The cash received from tax refunds dropped by 98.70% to CNY 9,566.87, indicating a significant reduction in tax refund receipts compared to the previous year[11] - The company did not receive any cash from financing activities related to employee stock incentives this period, a 100% decrease from CNY 70,060,000.00 in the previous year[12] - The company has not undergone an audit for the third quarter financial report, which may affect investor confidence[23] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[24] Investment Income - Investment income for the period was ¥38,329,882.06, representing a 78.09% increase year-on-year, attributed to higher returns from long-term deposits and financial products[10] - Investment cash inflows increased by 32.06% to CNY 6,501,596,227.45, primarily due to higher redemption amounts of financial investments[11] - The disposal of intangible assets resulted in a significant gain of CNY 2,050,698.58, reflecting a 1194.26% increase compared to the previous period[11]

证券代码：000650 证券简称：仁和药业 公告编号：2025-040 仁和药业股份有限公司 2025 年度第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次会议召开期间无增加、否决或变更提案的情况； 2、本次会议没有涉及变更以往股东大会已通过决议的情况； 一、会议召开和出席情况： (一)会议召开情况 1、会议召开的日期和时间 （1）现场会议召开时间：2025 年 10 月 29 日（星期三）下午 14:30。 7、本次会议的召集与召开程序、出席人员资格及表决程序符合《公司法》 《深圳证券交易所股票上市规则》和《公司章程》的有关规定。 (二) 会议出席情况 1、股东出席会议的总体情况 出席本次股东大会的股东（代理人）553 人，代表有表决权股份 437,280,277 股，占公司有表决权股份总数的 31.2357%。其中： 1 （2）网络投票时间：通过深交所交易系统进行网络投票的时间为 2025 年 10 月 29 日上午 9:15-9:25 和 9:30-11:30，下午 13:00-15:00； 通过深交所 ...

法律意见书 关于 仁和药业股份有限公司 2025 年第一次临时股东会的 法律意见书 致：仁和药业股份有限公司 江西求正沃德律师事务所（以下简称本所）接受仁和药业股份有限公司（以下简 称公司）的委托，指派律师出席见证公司 2025 年第一次临时股东会（以下简称本次会 议），并依据《中华人民共和国公司法》（以下简称《公司法》）、《上市公司股东会规则》 （以下简称《股东会规则》）、《仁和药业股份有限公司章程》（以下简称《公司章程》） 的规定，出具本法律意见书。 为出具本法律意见书，本所律师出席了本次会议，审查了公司提供的有关会议文 件、资料，并进行了必要的核查与验证。公司承诺，其已向本所提供的有关会议文件、 资料真实、完整、有效。 本所律师根据本法律意见书出具日前发生或存在的事实及有关的法律、法规和公 司章程的规定发表法律意见。本所同意，公司可以将本法律意见书作为本次会议公告 材料，随其他需公告的信息一起向公众披露，并依法对本所在其中发表的法律意见承 担法律责任。本法律意见书仅供本次会议之目的使用，未经本所书面同意，不得用于 其他任何目的或用途。 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责精神，现出具法 ...

Core Viewpoint - The article discusses the comprehensive deployment of China's 15th Five-Year Plan, emphasizing the development of a modern industrial system, a strong domestic market, and coordinated regional development, with a particular focus on emerging industries like brain-machine interfaces [2][3][4]. Industry Development - The 15th Five-Year Plan aims to cultivate new pillar industries, with a focus on future industries such as quantum technology, bio-manufacturing, hydrogen energy, nuclear fusion, brain-machine interfaces, embodied intelligence, and 6G mobile communication [3][4]. - Brain-machine interface technology is highlighted for its potential to transform economic structures and improve societal welfare, enabling applications in medical rehabilitation, industrial manufacturing, and consumer electronics [3][4]. Policy Support - The brain-machine interface has been officially recognized as a future industry by the Ministry of Industry and Information Technology and other departments, marking its entry into national strategic planning [4][5]. - The "Implementation Opinions" released in July 2025 set clear goals for the brain-machine interface industry, aiming for breakthroughs in core technologies by 2027 and positioning the industry among the world's leaders by 2030 [4][5]. Market Potential - The brain-machine interface industry is projected to create a market scale in the hundreds of billions, generating numerous high-skilled job opportunities and establishing a new competitive advantage for China in global technology [6][7]. - The industry is expected to evolve towards more precise, safer, and more accessible technologies during the 15th Five-Year Plan, with significant advancements in hardware and software capabilities [6][7]. Commercial Applications - Companies are actively engaging in the brain-machine interface space, with various business models targeting both B2B and B2C markets, including medical rehabilitation and consumer electronics [7][8]. - Examples of commercial initiatives include partnerships for developing implantable systems, clinical transformation centers, and innovative products like brain-controlled games and smart mattresses [7][8]. Conclusion - The emphasis on brain-machine interfaces in the 15th Five-Year Plan signifies a shift from following to leading in this technology, aligning with China's development philosophy centered on improving human welfare [8].

仁和药业股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 仁和药业股份有限公司(以下简称"公司")于2025年4月24日公司第九届董事会 第二十五次会议，审议通过了《关于续聘2025年度审计机构的议案》，经公司董事会 审计委员会提议，公司董事会同意续聘北京德皓国际会计师事务所(特殊普通合伙)（ 以下简称"北京德皓国际"）为公司2025年度财务审计机构（含内部控制审计），聘 期为一年。2025年5月23日该议案已经公司2024年度股东大会审议通过。具体内容详 见公司2025年4月26日、2025年5月24日在《证券日报》《证券时报》《中国证券报》 及巨潮资讯网（www.cninfo.com.cn）上披露的《公司关于关于续聘2025年度审计机 构的公告》（公告编号：2025-009）、《公司2024年度股东大会决议公告》（公告编 号：2025-026）。 近日，公司收到北京德皓国际出具的《关于变更仁和药业股份有限公司2025年度 审计项目签字注册会计师的函》，现将相关情况公告如下： 一、变更签字注册会计师的基本情况 北京德 ...

Group 1 - The core point of the article is that Renhe Pharmaceutical (SZ 000650) held its third board meeting of the tenth session on October 13, 2025, to review the proposal for amending the "Independent Director Work System" [1] - For the first half of 2025, Renhe Pharmaceutical's revenue composition was 99.25% from the pharmaceutical industry and 0.75% from other businesses [1] - As of the report date, Renhe Pharmaceutical's market capitalization was 8.6 billion yuan [1]

仁和药业股份有限公司 独立董事制度 （2025 年 10 月） 第一章 总则 第一条 仁和药业股份有限公司（以下简称"公司"）为规范独立董事行为，充 分发挥独立董事在公司治理中的作用，促进提高公司质量，根据《中华人民共和 国公司法》《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等法律、 行政法规、规范性文件和《仁和药业股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及公司主要 股东、实际控制人不存在直接或间接利害关系，或者其他可能影响其进行独立客 观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 个人的影响。 第三条 独立董事对公司及全体股东负有诚信与勤勉义务，应当按照法律、行政 法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、深圳证券交 易所业务规则和《公司章程》的规定，认真履行职责，在董事会中发挥参与决策、 监督制衡、专业咨询作用，维护公司整体利益，保护中小股东合法权益。 第四条 公司独立 ...

仁和药业股份有限公司 董事会审计委员会议事规则 （2025年10月） 第一章 总则 第一条 为强化仁和药业股份有限公司（以下简称"公司"）董事会决 策功能，确保董事会对经理层的有效监督，完善公司治理结构，根据《中 华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券 法》《上市公司治理准则》《上市公司独立董事管理办法》《深圳证券交 易所股票上市规则》及《深圳证券交易所上市公司自律监管指引第 1 号— —主板上市公司规范运作》等相关规范性文件的规定，制定本董事会审计 委员会议事规则。 第二条 董事会审计委员会是董事会设立的专门工作机构，对董事会负 责，向董事会报告工作。 第三条 审计委员会成员须保证足够的时间和精力履行委员会的工作 职责，勤勉尽责，切实有效地监督公司的外部审计，指导公司内部审计工 作，行使《公司法》规定的监事会的职权，促进公司建立有效的内部控制 并提供真实、准确、完整的财务报告。 第四条 公司须为审计委员会提供必要的工作条件，配备专门人员或机 构承担审计委员会的工作联络、会议组织、材料准备和档案管理等日常工 作。审计委员会履行职责时，公司管理层及相关部门须给予配合。 第二章 人员组成 ...